Numab Innovation AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Numab Innovation AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH348720D
  • |
  • Pages: 19
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Numab Innovation AG (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company's pipeline products include ND007, ND009, ND016, ND017, ND023, ND026, and ND021. Its ND007 is a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab's ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease, a chronic inflammation of the digestive tract that includes ulcerative colitis and Crohn's disease. The company's products are used in the treatment of inflammatory bowel disease, autoimmune disorders and metabolic disorders. It utilizes a proprietary antibody discovery and engineering technology to produce antibody Fv fragments. Numab is headquartered in Wadenswil, Switzerland.

Numab Innovation AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Numab Innovation AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Numab Innovation AG, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Numab Acquires ND003 From Sucampo 10

Venture Financing 11

Numab To Raise Funds Through Series A Financing 11

Partnerships 12

Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 12

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 13

Intarcia Therapeutics Enters into Co-Development Agreement with Numab 14

Licensing Agreements 15

Tillotts Pharma Enters into Licensing Agreement with Numab 15

Numab Innovation AG-Key Competitors 16

Numab Innovation AG-Key Employees 17

Numab Innovation AG-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Appendix 19

Methodology 19

About GlobalData 19

Contact Us 19

Disclaimer 19

List of Figures

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Numab Innovation AG, Pharmaceuticals & Healthcare, Key Facts 2

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Numab Innovation AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Numab Innovation AG, Deals By Therapy Area, 2012 to YTD 2018 8

Numab Innovation AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Numab Acquires ND003 From Sucampo 10

Numab To Raise Funds Through Series A Financing 11

Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 12

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 13

Intarcia Therapeutics Enters into Co-Development Agreement with Numab 14

Tillotts Pharma Enters into Licensing Agreement with Numab 15

Numab Innovation AG, Key Competitors 16

Numab Innovation AG, Key Employees 17

Numab Innovation AG, Subsidiaries 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Numab Innovation AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17250
Site License
USD 500 INR 34500
Corporate User License
USD 750 INR 51750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com